News
-
-
COMMUNIQUÉ DE PRESSE
BioNxt Reports Sublingual Cladribine Multiple Sclerosis Drug Milestones Including Large-Animal Study for Validation and Dosing Optimization
BioNxt Solutions provides update on Cladribine sublingual thin-film drug reformulation program, targeting treatment of multiple sclerosis with improved bioavailability and patient adherence -
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
Terry Lynch Continues as Capital Markets Advisor and BioNxt Retains Investor Relations Professionals
BioNxt Solutions Inc. announces Terry Lynch as capital markets advisor and retention of two investor relations professionals, Rob Grace and Blaine Ruzcki, for promotional activities. Company focuses on bioscience innovations with drug delivery platforms -
-